Akebia Therapeutics Unveils New Vafseo Clinical Data at ASN Kidney Week 2025

Reuters
2025.10.20 12:08
portai
I'm PortAI, I can summarize articles.

Akebia Therapeutics Inc. will present new clinical data on Vafseo® (vadadustat) at the ASN Kidney Week 2025 from November 5-9 in Houston, Texas. The presentation will include results from real-world evidence studies, focusing on the clinical benefits and dosing of Vafseo. Highlights include an oral session on the analysis of deaths and hospitalizations in CKD patients and four posters on dosing recommendations and safety. The studies aim to provide insights into the effectiveness of vadadustat compared to darbepoetin.

Akebia Therapeutics Inc. announced that it will present new data regarding Vafseo® (vadadustat) at the American Society of Nephrology Kidney Week 2025, scheduled for November 5-9, 2025, in Houston, Texas. The company will share results from ongoing real-world evidence studies and provide insights into the clinical benefits and dosing of Vafseo. Presentations include an oral session on the win-odds analysis of deaths and hospitalizations in patients taking vadadustat or darbepoetin alfa for chronic kidney disease (CKD)-related anemia undergoing dialysis, to be delivered by Dr. Glenn M. Chertow. Additionally, Akebia will present four posters on dosing recommendations, the safety of three times weekly vadadustat, and comparative responsiveness of vadadustat versus darbepoetin. The results of these studies are scheduled to be presented at the upcoming conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548340-en) on October 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.